PART 1: Before You Inject the Hype—How Medical Research Actually Works

A mouse study is not a human trial. “Promising” is not the same as “proven.” And unknown risk is not the same as low risk.

“Doc, what do you think about peptides?”

I get asked this question almost every day.

BPC-157. TB-500. CJC-1295. Ipamorelin. MOTS-c. New names seem to appear almost as quickly as new social media posts promoting them.

Someone hears about a peptide on a podcast. An influencer says it transformed their recovery. A clinic promises better sleep, more muscle, faster healing, or even longer life.

And suddenly, an experimental compound starts looking like established medicine.

But before we talk about individual peptides, we need to understand one thing:

How do we actually know whether a treatment works—and whether it is safe?

I Am Not Anti-Peptide

Quite the opposite.

Peptides have already transformed medicine.

Insulin is a peptide hormone. Modern incretin medications have revolutionized the treatment of obesity and diabetes. Other peptide-based drugs are used throughout endocrinology and many other areas of medicine.

And some experimental peptides being discussed today may eventually become important therapies.

But there is a huge difference between a medication studied in thousands of humans and a compound that produced an interesting result in a mouse.

They may both be peptides. They do not have the same level of evidence.

How Does an Idea Become Medicine?

Medical research usually moves through several stages:

Laboratory research → Animal research → Human trials → Regulatory review → Ongoing safety monitoring

Each step answers different questions.

Laboratory Research

Researchers may first study a compound in cells or tissues.

This can help show how something might work.

But a cell in a laboratory dish is not a person.

A molecule entering the human body may affect the immune system, metabolism, hormones, organs, and biological pathways that were never part of the original experiment.

So when someone says:

“Studies show this works.”

My first question is:

What kind of studies?

Animal Research

Animal studies are valuable. They can help researchers understand biological effects, dosing, metabolism, and possible toxicity.

But animals and humans are different.

Something that dramatically improves healing in a mouse may not work in a human. Something that appears safe during a short animal experiment may create problems when people use it for months or years.

So when I see exciting animal research, my response is not:

“It doesn't work.”

My response is:

“Great. Now let's study humans.”

That is how science is supposed to work.

Then Come Human Trials

Even human research exists on different levels.

Phase 1

Early studies primarily examine safety, dosing, and how the body processes a drug.

Phase 2

Researchers begin asking whether it appears to work.

Phase 3

Larger studies provide much stronger information about benefits and risks.

This distinction matters.

A compound being “studied in humans” does not mean it has been proven effective.

Twenty people using something for a few weeks cannot tell us what may happen when thousands of people use it for years.

Study size matters.

Study duration matters.

What researchers actually measured matters.

A Better Number Does Not Always Mean a Healthier Person

This is another place where hype can get ahead of science.

A peptide may change a hormone level, inflammatory marker, growth factor, or body-composition measurement.

Interesting?

Absolutely.

But the more important questions are:

Did people actually feel better?

Did they heal faster?

Did they function better?

Did they avoid disease?

Did they live longer?

And what risks came with the benefit?

A biological effect is not automatically a meaningful health outcome.

The Most Dangerous Phrase: “There Is No Evidence It Is Dangerous”

Be careful.

That statement can mean:

We studied this extensively and have not found a major safety problem.

Or it can mean:

Almost nobody has studied this properly, so we have no idea what the risks are.

Those are completely different situations.

UNKNOWN RISK ≠ LOW RISK

Not knowing that something is dangerous is not the same as knowing that it is safe.

And What Is Actually in the Vial?

This question is often overlooked.

Even when a particular molecule is scientifically interesting, the product being sold still matters.

Is it actually what the label says?

Is the dose accurate?

Is it sterile?

Is it contaminated?

Has it been stored correctly?

A scientific study using a carefully manufactured product does not automatically validate every vial carrying the same peptide name.

The molecule matters. But so do purity, sterility, dose, and manufacturing quality.

Then Came Social Media

Social media has helped patients become more informed and engaged.

But it has also created a major problem:

Social media moves much faster than science.

A good clinical trial may take years.

A viral video takes seconds.

And the algorithm does not ask whether a treatment has been properly studied.

It asks whether you clicked.

That is why repetition can begin to look like proof.

But:

Popularity is not a phase of clinical research.

Testimonials are not clinical trials.

A million views do not equal one well-designed human study.

My Position

I am excited about the future of peptide medicine.

Some of today's experimental compounds may become tomorrow's important therapies.

Others will fail.

Some may reveal risks we do not yet understand.

That is normal.

That is science.

What concerns me is when we skip the process—when animal data becomes a treatment claim, a theoretical mechanism becomes a guarantee, and patients effectively become the experiment.

Innovation is important.

But we should never have to abandon scientific standards to pursue it.

Before Trying Any New Peptide, Ask Five Questions

Has it actually been studied in humans?

How many humans?

What benefit was actually proven?

How long were people followed?

Where did the product actually come from?

Those five questions can eliminate a remarkable amount of medical misinformation.

The Bottom Line

I believe peptide medicine has an exciting future.

But the future of medicine should be built on evidence—not algorithms.

We should be open to innovation while remaining honest about what we know, what we do not know, and what may still carry unknown risk.

Sometimes the most responsible answer a physician can give is:

“We don't know yet.”

That may not go viral.

But it may keep patients safe.

Next: Part 2—What Exactly Is a Peptide?

Next, we will look at what peptides actually are, how they work in the body, why some have become extraordinary medications—and what separates established peptide medicine from the rapidly expanding world of experimental peptide therapy.

Then we will begin examining the peptides everyone is asking about, one by one.

Evidence over hype. Science over social media. Patient safety first.

— Alex Foxman, MD, FACP, ABOM

Double Board-Certified in Internal Medicine & Obesity Medicine

Beverly Hills Institute

This article is for general educational purposes and does not constitute individualized medical advice.